From the moment I started covering Ra Medical Systems I could immediately see how the excimer laser could be used beyond the peripherals. DABRA's first clearance is for crossing CTOs in the peripherals. But I've watched doctors in Italy successful go off-label using it for veins and I've seen several doctors in the U.S. using it off-label to treat in-stent restenosis, which has proven to me it has much greater value. Next, I can imagine it being used in coronary vessels. And doctors I've spoken with throughout my journey concur with this direction as it's laid out in Ra Medical's S1 Filing with the SEC.
The S1 states, "DABRA is cleared by the U.S. Food and Drug Administration, or FDA, as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, which includes peripheral artery disease, or PAD, which commonly occurs in the legs. We intend to pursue additional uses for DABRA, including seeking regulatory clearance for the use of DABRA as a tool for the treatment of vascular blockages associated with coronary artery disease, or CAD, in-stent restenosis, and other venous and arterial occlusions, or blockages in the veins or arteries."